The Precision Cancer Consortium (PCC) and Massive Bio have conducted a comprehensive study on the efficacy of Massive Bio’s artificial intelligence (AI) system for clinical trial matching. The study evaluated the system’s ability to refine the matching process using real-world clinical and genomic data for a multi-study oncology platform.

Typically, screening patients for cancer trials involves manual labor, extending the process to approximately 25 minutes per trial. This exhaustive process restricts patient access to suitable trials and hinders enrollment rates. To address this challenge, Massive Bio and PCC introduced a multi-trial matching method that incorporates Next-Generation Sequencing (NGS) results and AI to enhance accuracy and efficiency, primarily for targeted therapies.

Massive Bio’s AI system leverages computer vision and natural language processing to extract structured clinical parameters from medical records. This system harnesses the power of GPT-4 Large Language Model and has been specifically optimized for oncology and biomarker-specific scenarios. Using an AI-driven recommendation algorithm, it matches patients to inclusion/exclusion criteria for over 14,000 active cancer trials.

The study’s findings were compelling. The integration of NGS and AI in the multi-trial matching framework significantly increased patient eligibility for various tumor types, doubling the potential enrollment pool. Furthermore, it boosted matching efficiency by twelvefold for specific tumor profiles, greatly reducing manual intervention.

This study’s success demonstrates AI’s transformative potential in streamlining the clinical trial matching process. It reduces the time and resources required, enabling greater patient access to potentially life-saving therapies. Future endeavors aim to expand this analysis nationwide to validate these promising results further.

Source link: http://www.businesswire.com/news/home/20240528545627/en/PCC-and-Massive-Bio-Validate-Existing-AI-System-in-Groundbreaking-and-Largest-Multi-Sponsor-Clinical-Trial-Matching-Study

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.